SCHEMBL4559441

SCHEMBL4559441

CCC(C)(C#N)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.42
ESR2 Q92731 1/20 0.42
KIF11 P52732 2/20 0.41
PRKCQ Q04759 1/20 0.40
LMNA P02545 1/20 0.39
CYP2C9 P11712 1/20 0.36
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CYP2D6 P10635 1/20 0.35
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
OPRM1 P35372 1/20 0.35
DRD3 P35462 1/20 0.35
MME P08473 1/20 0.35
ACE P12821 1/20 0.35
CYP19A1 P11511 1/20 0.35
CYP1A1 P04798 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP1B1 Q16678 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1492823 0.88 CYP2D6 (0.43) ESR1ESR2PRKCQLMNACYP2C9
SCHEMBL24302110 0.88 CYP2D6 (0.43) ESR1ESR2PRKCQLMNACYP2C9
SCHEMBL1626918 0.77 ESR1 (0.44) ESR1ESR2PRKCQSMN1; SMN2L3MBTL1
SCHEMBL10369991 0.77 ESR1 (0.44) ESR1ESR2PRKCQLMNACYP2C9
SCHEMBL682897 0.77 ESR1 (0.68) ESR1ESR2LMNA
SCHEMBL8503879 0.77 ESR1 (0.44) ESR1ESR2KIF11PRKCQLMNA
SCHEMBL14339779 0.75 CYP2A6 (0.40) ESR1ESR2PRKCQLMNASMN1; SMN2
SCHEMBL700444 0.74 KIF11 (0.48) KIF11LMNACYP2C9MAPTSMN1; SMN2
SCHEMBL3240819 0.73 CYP2D6 (0.44) ESR1ESR2LMNACYP2D6DRD2
SCHEMBL7900944 0.73 CYP2C9 (0.47) CYP2C9MAPTSMN1; SMN2L3MBTL1MME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291988-A1 Reversible Inhibitors of Monoamine Oxidase A and B MERCK FROSST CANADA LTD. (CA) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291988-A1 Reversible Inhibitors of Monoamine Oxidase A and B MAOB, MAOA, XDH ESR1 1417/4885ESR2 1622/4885KIF11 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.